Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier:
NCT01133626
First received: May 27, 2010
Last updated: May 31, 2012
Last verified: May 2012
Results First Received: April 23, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Condition: Perennial Allergic Rhinitis
Interventions: Drug: Placebo Nasal Aerosol
Drug: Prednisone capsules
Drug: Placebo Prednisone Capsules
Drug: Beclomethasone dipropionate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 139 patients were screened and 128 patients were enrolled in the study and participated in the Run-in Period. Of the 128 enrolled patients, 107 were randomized to study treatment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
During the 7 to 14 day Run-in Period (prior to randomization), participants self-administered a single-blind placebo nasal aerosol once daily in the morning.

Reporting Groups
  Description
BDP HFA 320 µg/Day Participants self-administered 4 actuations (two per nostril) of 80 µg beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Placebo Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Placebo/Prednisone Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.

Participant Flow:   Overall Study
    BDP HFA 320 µg/Day     Placebo     Placebo/Prednisone  
STARTED     50     46     11  
Safety Population     50 [1]   46 [1]   11 [1]
Per Protocol Population     48 [2]   41 [2]   9 [2]
COMPLETED     49     41     9  
NOT COMPLETED     1     5     2  
Adverse Event                 0                 1                 0  
Withdrawal by Subject                 1                 2                 2  
Not specified                 0                 2                 0  
[1] Participants who received at least 1 dose of study drug
[2] Received >=1 dose of study drug and >=1 post-baseline assessment prior to major protocol deviation.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
BDP HFA 320 µg/Day Participants self-administered 4 actuations (two per nostril) of 80 µg beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Placebo Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
Placebo/Prednisone Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
Total Total of all reporting groups

Baseline Measures
    BDP HFA 320 µg/Day     Placebo     Placebo/Prednisone     Total  
Number of Participants  
[units: participants]
  48     41     9     98  
Age [1]
[units: years]
Mean ± Standard Deviation
  28.3  ± 10.0     26.6  ± 10.6     26.2  ± 11.9     27.4  ± 10.4  
Gender  
[units: participants]
       
Female     25     22     7     54  
Male     23     19     2     44  
Race/Ethnicity, Customized  
[units: participants]
       
Hispanic or Latino     18     17     2     37  
Not Hispanic or Latino     30     24     7     61  
Race/Ethnicity, Customized [2]
[units: participants]
       
American Indian or Alaska Native     0     0     1     1  
Asian     1     0     0     1  
Black or African American     7     2     1     10  
White     42     38     7     87  
Unknown or Not Reported     0     1     0     1  
Body Mass Index  
[units: kg/m^2]
Mean ± Standard Deviation
  27.9  ± 7.9     27.0  ± 6.2     28.4  ± 7.9     27.6  ± 7.2  
[1] Demographic data are provided for the Per Protocol population.
[2] A participant may select more than one race type.



  Outcome Measures

1.  Primary:   The 24-hour Serum Cortisol Weighted Mean After 42 Days of Treatment   [ Time Frame: Day 0 (Baseline), Day 42 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Director, Clinical Research
Organization: Teva Branded Pharmaceutical Products, R&D Inc.
phone: 215-591-3000
e-mail: ustevatrials@tevapharm.com


Publications of Results:
Hampel FC, Ratner PH, Miller SD, Melchior A, Dunbar SA, Tantry SK, Dorinsky PM. Once-daily treatment with beclomethasone dipropionate hydrofluoroalkane nasal aerosol (320 mcg/d) is not associated with hypothalamic-pituitary-adrenal axis suppression in adolescent subjects with perennial allergic rhinitis. J Allergy Clin Immunol 2012; 129:AB188
Ratner PH, Miller SD, Hampel FC, A, Dunbar SA, Tantry SK, Dorinsky PM (2011). BDP HFA Nasal Aerosol 320 μg Once Daily g Once Daily Is Not Associated with HPA-Axis Suppression in Subjects With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol. 107(11):A118.

Publications automatically indexed to this study:

Responsible Party: Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier: NCT01133626     History of Changes
Other Study ID Numbers: BDP-AR-304
Study First Received: May 27, 2010
Results First Received: April 23, 2012
Last Updated: May 31, 2012
Health Authority: United States: Food and Drug Administration